TabletsClinical Overview
Citicoline and Piracetam is a synergistic neuroprotective and nootropic formulation. Citicoline serves as an essential intermediate in the biosynthesis of structural neuronal membrane phosphatidylcholine and raises brain acetylcholine and dopamine levels, while piracetam, a cyclic GABA derivative, allosterically modulates AMPA receptors, improves erythrocyte deformability, enhances microvascular cerebral blood flow, and elevates neuronal ATP turnover. Indicated for cognitive dysfunction, acute ischemic stroke recovery, vascular dementia, post-concussion syndrome, and senile memory impairment.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally with water, divided twice daily, preferably before or with meals. Maintain consistent dosing as prescribed by the neurologist.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Insomnia, nervousness, hyperkinesia, headache, nausea, diarrhea, weight gain. Rare/Severe: Severe psychomotor agitation, bleeding tendencies (due to platelet inhibition), and hypotension.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Contraindicated in severe renal impairment (CrCl < 20 mL/min) and cerebral hemorrhage. Exercise caution in patients with underlying bleeding disorders or taking anticoagulants/antiplatelets due to piracetam's antiplatelet effects.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified pharmacist before initiating, modifying, or substituting any medication regimen.
Citicoline Tablets 500mg
Citicoline (Cytidine 5'-diphosphocholine / CDP-Choline) is a physiological intermediate in the biosynthesis of phosphatidylcholine, the major phospholipid component of neuronal membranes. It repairs damaged neuronal membranes, accelerates reabsorption of cerebral edema, inhibits free fatty acid release, and promotes acetylcholine and dopamine synthesis in the brain. Indicated for acute and subacute ischemic stroke recovery, traumatic brain injury (TBI), cognitive impairment, and vascular dementia.
Piracetam Syrup 500mg per 5ml
Piracetam is the prototypical racetam nootropic agent. It binds to neuronal membranes to restore membrane fluidity, allosterically potentiates AMPA-type glutamate receptors, and improves cerebral microcirculation by reducing platelet aggregation and erythrocyte adhesion to vascular endothelium. Indicated for cortical myoclonus (as adjunctive therapy), cognitive disorders, post-stroke rehabilitation, and vertigo.
Piracetam Tablets 400mg
Piracetam is the prototypical racetam nootropic agent. It binds to neuronal membranes to restore membrane fluidity, allosterically potentiates AMPA-type glutamate receptors, and improves cerebral microcirculation by reducing platelet aggregation and erythrocyte adhesion to vascular endothelium. Indicated for cortical myoclonus (as adjunctive therapy), cognitive disorders, post-stroke rehabilitation, and vertigo.
Piracetam Tablet 800 mg
Piracetam is the prototypical racetam nootropic agent. It binds to neuronal membranes to restore membrane fluidity, allosterically potentiates AMPA-type glutamate receptors, and improves cerebral microcirculation by reducing platelet aggregation and erythrocyte adhesion to vascular endothelium. Indicated for cortical myoclonus (as adjunctive therapy), cognitive disorders, post-stroke rehabilitation, and vertigo.